| The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms R Alaggio, C Amador, I Anagnostopoulos, AD Attygalle, IBO Araujo, ... Leukemia 36 (7), 1720-1748, 2022 | 1484 | 2022 |
| Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment O Naveiras, V Nardi, PL Wenzel, PV Hauschka, F Fahey, GQ Daley Nature 460 (7252), 259-263, 2009 | 1220 | 2009 |
| A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity BC Grabiner, V Nardi, K Birsoy, R Possemato, K Shen, S Sinha, A Jordan, ... Cancer discovery 4 (5), 554-563, 2014 | 480* | 2014 |
| Mechanisms and implications of imatinib resistance mutations in BCR-ABL V Nardi, M Azam, GQ Daley Current opinion in hematology 11 (1), 35-43, 2004 | 260 | 2004 |
| Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer JJ Lin, SV Liu, CE McCoach, VW Zhu, AC Tan, S Yoda, J Peterson, A Do, ... Annals of Oncology 31 (12), 1725-1733, 2020 | 166 | 2020 |
| Pediatric acute lymphoblastic leukemia, version 2.2020, NCCN clinical practice guidelines in oncology P Brown, H Inaba, C Annesley, J Beck, S Colace, M Dallas, K DeSantes, ... Journal of the National Comprehensive Cancer Network 18 (1), 81-112, 2020 | 153 | 2020 |
| Merkel cell carcinoma: 30-year experience from a single institution JA Santamaria-Barria, GM Boland, BY Yeap, V Nardi, D Dias-Santagata, ... Annals of surgical oncology 20, 1365-1373, 2013 | 153 | 2013 |
| Clinical sensitivity and interpretation of PCR and serological COVID‐19 diagnostics for patients presenting to the hospital TE Miller, WFG Beltran, AZ Bard, T Gogakos, MN Anahtar, MG Astudillo, ... The FASEB Journal 34 (10), 13877, 2020 | 149 | 2020 |
| An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients NG Chau, C Ma, K Danga, H Al-Sayegh, V Nardi, R Barrette, CS Lathan, ... JNCI Cancer Spectrum 4 (2), pkz094, 2020 | 142 | 2020 |
| Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma L Goyal, A Govindan, RA Sheth, V Nardi, LS Blaszkowsky, JE Faris, ... The oncologist 20 (9), 1019-1027, 2015 | 141 | 2015 |
| Recurrent EML4–NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy AJ Church, ML Calicchio, V Nardi, A Skalova, A Pinto, DA Dillon, ... Modern Pathology 31 (3), 463-473, 2018 | 131 | 2018 |
| Detection of enhancer-associated rearrangements reveals mechanisms of oncogene dysregulation in B-cell lymphoma RJH Ryan, Y Drier, H Whitton, MJ Cotton, J Kaur, R Issner, S Gillespie, ... Cancer discovery 5 (10), 1058-1071, 2015 | 127 | 2015 |
| Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance M Azam, V Nardi, WC Shakespeare, CA Metcalf III, RS Bohacek, Y Wang, ... Proceedings of the National Academy of Sciences 103 (24), 9244-9249, 2006 | 125 | 2006 |
| Activation of PI3K signaling in Merkel cell carcinoma V Nardi, Y Song, JA Santamaria-Barria, AK Cosper, Q Lam, AC Faber, ... Clinical Cancer Research 18 (5), 1227-1236, 2012 | 123 | 2012 |
| Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment V Nardi, PM Sadow, D Juric, D Zhao, AK Cosper, K Bergethon, ... Clinical cancer research 19 (2), 480-490, 2013 | 117 | 2013 |
| Identification of ALK rearrangements in malignant peritoneal mesothelioma YP Hung, F Dong, JC Watkins, V Nardi, R Bueno, P Dal Cin, JJ Godleski, ... JAMA oncology 4 (2), 235-238, 2018 | 116 | 2018 |
| A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma L Goyal, H Zheng, MB Yurgelun, TA Abrams, JN Allen, JM Cleary, ... Cancer 123 (11), 1979-1988, 2017 | 110 | 2017 |
| Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum JA Bennett, V Nardi, M Rouzbahman, V Morales-Oyarvide, GP Nielsen, ... Modern Pathology 30 (10), 1489-1503, 2017 | 104 | 2017 |
| Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms V Nardi, KM Winkfield, CY Ok, A Niemierko, MJ Kluk, EC Attar, ... Journal of clinical oncology 30 (19), 2340, 2012 | 97 | 2012 |
| Targetable vulnerabilities in T-and NK-cell lymphomas identified through preclinical models SY Ng, N Yoshida, AL Christie, M Ghandi, NV Dharia, J Dempster, ... Nature communications 9 (1), 2024, 2018 | 93 | 2018 |
